Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Aurobindo gets tentative FDA ok for lopinavir/ritonavir

This article was originally published in Scrip

Executive Summary

Aurobindo Pharma has received tentative US FDA approval for lopinavir/ritonavir tablets 100/25mg and 200/50mg, generic versions of Abbott Laboratories' antiretroviral Kaletra tablets. This is the first tentative approval of a generic version of Kaletra under PEPFAR (President's Emergency Plan for AIDS Relief). Aurobindo, which recently entered a licensing and supply deal with Pfizer for a range of generics (scripnews.com, March 4th, 2009), now has 93 ANDA approvals (66 final and 27 tentative approvals) from the FDA.

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC000774

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel